×
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
NASDAQ:AMGN

Amgen Stock Forecast, Price & News

$245.37
+2.28 (+0.94%)
(As of 06/24/2022 06:55 PM ET)
Add
Compare
Today's Range
$242.88
$246.00
50-Day Range
$230.71
$256.74
52-Week Range
$198.64
$258.45
Volume
4.53 million shs
Average Volume
3.27 million shs
Market Capitalization
$131.08 billion
P/E Ratio
24.15
Dividend Yield
3.16%
Price Target
$242.57
30 days | 90 days | 365 days | Advanced Chart

Receive AMGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amgen and its competitors with MarketBeat's FREE daily newsletter.

AMGN Stock Forecast (MarketRank)

Overall MarketRank

2.62 out of 5 stars

Medical Sector

84th out of 1,411 stocks

Biological Products, Except Diagnostic Industry

13th out of 215 stocks

Analyst Opinion: 1.1Community Rank: 4.9Dividend Strength: 3.3Insider Behavior: 2.5Valuation: 1.3 5 -4 -3 -2 -1 -
Amgen logo

About Amgen (NASDAQ:AMGN)

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

AMGN Stock News Headlines

3 Biotech Stocks to Buy Now
See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:AMGN
CUSIP
03116210
Employees
24,200
Year Founded
1980

Company Calendar

Last Earnings
4/27/2022
Ex-Dividend for 6/8 Dividend
5/16/2022
Dividend Payable
6/08/2022
Today
6/27/2022
Next Earnings (Estimated)
8/02/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$242.57
High Stock Price Forecast
$290.00
Low Stock Price Forecast
$185.00
Forecasted Upside/Downside
-1.1%
Consensus Rating
Hold
Rating Score (0-4)
2.14285714285714
Research Coverage
14 Analysts

Profitability

Net Income
$5.89 billion
Pretax Margin
24.77%

Debt

Sales & Book Value

Annual Sales
$25.98 billion
Cash Flow
$23.64 per share
Book Value
$12.00 per share

Miscellaneous

Free Float
531,743,000
Market Cap
$131.08 billion
Optionable
Optionable
Beta
0.57

Social Links















Amgen Frequently Asked Questions

Should I buy or sell Amgen stock right now?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amgen in the last year. There are currently 1 sell rating, 10 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Amgen stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMGN, but not buy additional shares or sell existing shares.
View analyst ratings for Amgen
or view top-rated stocks.

What is Amgen's stock price forecast for 2022?

14 analysts have issued 1 year price objectives for Amgen's stock. Their AMGN stock forecasts range from $185.00 to $290.00. On average, they predict Amgen's share price to reach $242.57 in the next year. This suggests that the stock has a possible downside of 1.1%.
View analysts' price targets for Amgen
or view top-rated stocks among Wall Street analysts.

How has Amgen's stock performed in 2022?

Amgen's stock was trading at $224.97 on January 1st, 2022. Since then, AMGN stock has increased by 9.1% and is now trading at $245.37.
View the best growth stocks for 2022 here
.

When is Amgen's next earnings date?

Amgen is scheduled to release its next quarterly earnings announcement on Tuesday, August 2nd 2022.
View our earnings forecast for Amgen
.

How were Amgen's earnings last quarter?

Amgen Inc. (NASDAQ:AMGN) posted its quarterly earnings results on Wednesday, April, 27th. The medical research company reported $4.25 EPS for the quarter, beating the consensus estimate of $4.22 by $0.03. The medical research company earned $6.24 billion during the quarter, compared to the consensus estimate of $6.09 billion. Amgen had a trailing twelve-month return on equity of 165.95% and a net margin of 21.75%. During the same quarter in the previous year, the company earned $3.70 EPS.
View Amgen's earnings history
.

How often does Amgen pay dividends? What is the dividend yield for Amgen?

Amgen declared a quarterly dividend on Wednesday, March 2nd. Investors of record on Tuesday, May 17th will be given a dividend of $1.94 per share on Wednesday, June 8th. This represents a $7.76 dividend on an annualized basis and a dividend yield of 3.16%. The ex-dividend date is Monday, May 16th.
View Amgen's dividend history
.

Is Amgen a good dividend stock?

Amgen(NASDAQ:AMGN) pays an annual dividend of $7.76 per share and currently has a dividend yield of 3.16%. Amgen has been increasing its dividend for 11 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio of Amgen is 76.38%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, Amgen will have a dividend payout ratio of 40.97% next year. This indicates that Amgen will be able to sustain or increase its dividend.
View Amgen's dividend history.

What guidance has Amgen issued on next quarter's earnings?

Amgen issued an update on its FY22 earnings guidance on Wednesday, April, 27th. The company provided earnings per share (EPS) guidance of $17.00-18.00 for the period, compared to the consensus EPS estimate of $17.61. The company issued revenue guidance of $25.4-26.5 billion, compared to the consensus revenue estimate of $26.09 billion.

Who are Amgen's key executives?

Amgen's management team includes the following people:
  • Mr. Robert A. Bradway, Chairman, CEO & Pres (Age 59, Pay $5.81M)
  • Mr. Peter H. Griffith, Exec. VP & CFO (Age 63, Pay $2.66M)
  • Mr. Esteban Santos, Exec. VP of Operations (Age 54, Pay $2.61M)
  • Dr. David M. Reese M.D., Exec. VP of R&D (Age 59, Pay $2.79M)
  • Mr. Murdo Gordon, Exec. VP of Global Commercial Operations (Age 55, Pay $2.82M)
  • Ms. Linda H. Louie, VP of Fin. & Chief Accounting Officer
  • Mr. Mike Zahigian, Sr. VP & Chief Information Officer
  • Mr. Arvind Sood, VP of Investor Relations
  • Mr. Jonathan P. Graham, Exec. VP, Gen. Counsel & Sec. (Age 61) (LinkedIn Profile)
  • Ms. Nancy A. Grygiel, Sr. VP of Worldwide Compliance & Bus. Ethics and Chief Compliance Officer (Age 54) (LinkedIn Profile)

What is Robert A. Bradway's approval rating as Amgen's CEO?

806 employees have rated Amgen CEO Robert A. Bradway on Glassdoor.com. Robert A. Bradway has an approval rating of 91% among Amgen's employees. This puts Robert A. Bradway in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Amgen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amgen investors own include Johnson & Johnson (JNJ), NVIDIA (NVDA), Intel (INTC), Cisco Systems (CSCO), Pfizer (PFE), AbbVie (ABBV), Walt Disney (DIS), AT&T (T), Alibaba Group (BABA) and Home Depot (HD).

What is Amgen's stock symbol?

Amgen trades on the NASDAQ under the ticker symbol "AMGN."

Who are Amgen's major shareholders?

Amgen's stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (9.37%), Vanguard Group Inc. (8.86%), State Street Corp (5.71%), Capital Research Global Investors (3.45%), Primecap Management Co. CA (2.94%) and Charles Schwab Investment Management Inc. (1.65%). Company insiders that own Amgen stock include Cynthia M Patton, David Piacquad, David W Meline, Jonathan P Graham, Jonathan P Graham, Nancy A Grygiel, Nancy A Grygiel, R Sanders Williams, Ronald D Sugar and Ronald D Sugar.
View institutional ownership trends for Amgen
.

Which major investors are selling Amgen stock?

AMGN stock was sold by a variety of institutional investors in the last quarter, including Capital Research Global Investors, Capital International Investors, Healthcare of Ontario Pension Plan Trust Fund, Renaissance Technologies LLC, Nordea Investment Management AB, Capitolis Advisors LLC, Bank of Nova Scotia, and Toronto Dominion Bank. Company insiders that have sold Amgen company stock in the last two years include Jonathan P Graham, Nancy A Grygiel, R Sanders Williams, and Ronald D Sugar.
View insider buying and selling activity for Amgen
or view top insider-selling stocks.

Which major investors are buying Amgen stock?

AMGN stock was purchased by a variety of institutional investors in the last quarter, including Jane Street Group LLC, Aaron Wealth Advisors LLC, Arrowstreet Capital Limited Partnership, Vanguard Group Inc., State Street Corp, Invesco Ltd., Verity Asset Management Inc., and Swiss National Bank.
View insider buying and selling activity for Amgen
or or view top insider-buying stocks.

How do I buy shares of Amgen?

Shares of AMGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Amgen's stock price today?

One share of AMGN stock can currently be purchased for approximately $245.37.

How much money does Amgen make?

Amgen (NASDAQ:AMGN) has a market capitalization of $131.08 billion and generates $25.98 billion in revenue each year. The medical research company earns $5.89 billion in net income (profit) each year or $10.16 on an earnings per share basis.

How many employees does Amgen have?

Amgen employs 24,200 workers across the globe.

Does Amgen have any subsidiaries?

The following companies are subsidiares of Amgen: Abgenix, Alantos Pharmaceuticals, Amgen Canada Inc., Amgen Europe GmbH, Amgen Fremont Inc., Amgen Global Finance B.V., Amgen GmbH Germany, Amgen Ilaç Ticaret Limited Şirketi, Amgen K-A Inc., Amgen Manufacturing Limited, Amgen Research Munich GmbH, Amgen Rockville Inc., Amgen S.A., Amgen S.A.S., Amgen S.p.A., Amgen SF LLC, Amgen Singapore Manufacturing Pte. Ltd., Amgen Technology Ireland Unlimited Company, Amgen Technology Limited, Amgen USA Inc., Amgen Worldwide Holdings B.V., Avidia, Bergamo, BioVex, BioVex Inc., Catherex, Catherex, DeCODE Genetics, Dezima Pharma, Filgrastim and Pegfilgrastim, Five Prime Therapeutics, Five Prime Therapeutics Inc., Gensenta İlaç Sanayi ve Ticaret Anonim Şirketi, Ilypsa, Immunex, Immunex Corporation, Immunex Rhode Island Corporation, KAI Pharmaceuticals, KAI Pharmaceuticals Inc., Kinetix Pharmaceuticals, Laboratorio Quimico Farmaceutico Bergamo, MN Pharmaceuticals, Micromet, Nuevolution, Onyx Pharmaceuticals, Onyx Pharmaceuticals Inc., Onyx Therapeutics Inc., Otezla, Rodeo Therapeutics, Saga Investments Coöperatief U.A., Synergen, TeneoBio, TeneoBio Inc., Tularik, deCODE Genetics ehf, and llypsa Inc..
Read More

When was Amgen founded?

Amgen was founded in 1980.

How can I contact Amgen?

Amgen's mailing address is ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA, 91320. The official website for Amgen is www.amgen.com. The medical research company can be reached via phone at (805) 447-1000, via email at [email protected], or via fax at 805-447-1010.

This page (NASDAQ:AMGN) was last updated on 6/27/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.